Literature DB >> 10969656

Platelet activating factor acetylhydrolase decreases lung reperfusion injury.

J D Kim1, C J Baker, R F Roberts, S H Darbinian, K A Marcus, S M Quardt, V A Starnes, M L Barr.   

Abstract

BACKGROUND: Ischemia-reperfusion injury involves free radical production, polymorphonuclear neutrophil chemotaxis/degranulation, and production of proteolytic enzymes, complement components, coagulation factors, and cytokines. Activated polymorphonuclear neutrophils, endothelial cells, and macrophages produce platelet activating factor, which further promotes these inflammatory reactions. The recently cloned plasma form of platelet activating factor-acetylhydrolase (PAF-AH) demonstrates antiinflammatory effects by degrading platelet activating factor. We evaluated the effects of PAF-AH in an isolated perfused rat lung model by adding it to the flush solutions or to the reperfusion blood.
METHODS: Rat lungs were isolated, flushed with EuroCollins (EC) or University of Wisconsin (UW) solution, stored at 4 degrees C for 6 or 12 hours, and reperfused using a cross-circulating syngeneic support rat. During reperfusion, oxygenation, compliance, and capillary filtration coefficient were calculated. There were four groups in the study; group I (control) had no PAF-AH added, group II had PAF-AH added to the flush solution, group III had PAF-AH added to reperfusion blood, and group IV had PAF-AH added to both flush solution and reperfusion blood.
RESULTS: After 6 hours of storage, oxygenation, compliance, and capillary filtration coefficient significantly improved for EC in group IV. For UW, oxygenation improved in group IV whereas compliance improved in groups II, III, and IV. After 12 hours of storage, compliance improved for EC in group IV and capillary filtration coefficient improved in groups III and IV. For UW, oxygenation and compliance improved in groups II and IV, whereas capillary filtration coefficient improved in group IV.
CONCLUSIONS: Addition of PAF-AH to intracellular organ preservation solutions and to the blood reperfusate significantly improves postreperfusion oxygenation and compliance, and reduces lung capillary permeability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969656     DOI: 10.1016/s0003-4975(00)01405-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  The impact of platelet-activating factor (PAF)-like mediators on the functional activity of neutrophils: anti-inflammatory effects of human PAF-acetylhydrolase.

Authors:  T W Kuijpers; J M van den Berg; A T Tool; D Roos
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  Taurine attenuates lung ischemia-reperfusion injury after lung transplantation in rats.

Authors:  Leyla Guler; Murat Tavlasoglu; Orhan Yucel; Adem Guler; Mehmet Ali Sahin; Mustafa Kurkluoglu; Yusuf Sirin; Ayse Eken; Mehmet Gamsizkan; Mehmet Dakak; Sedat Gurkok; Onur Genc
Journal:  J Anesth       Date:  2013-11-06       Impact factor: 2.078

Review 3.  Inflammatory response to pulmonary ischemia-reperfusion injury.

Authors:  Calvin S H Ng; Song Wan; Ahmed A Arifi; Anthony P C Yim
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor-deficient mice and PAF receptor antagonist treatment.

Authors:  Danielle G Souza; Vanessa Pinho; Adriana C Soares; Takao Shimizu; Satoshi Ishii; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Hypoxia and hyperoxia potentiate PAF receptor-mediated effects in newborn ovine pulmonary arterial smooth muscle cells: significance in oxygen therapy of PPHN.

Authors:  Mona Hanouni; Gilberto Bernal; Shaemion McBride; Vincent Reginald F Narvaez; Basil O Ibe
Journal:  Physiol Rep       Date:  2016-06

Review 6.  Hemoglobin-Based Oxygen Carriers: Potential Applications in Solid Organ Preservation.

Authors:  Min Cao; Guoqing Wang; Hongli He; Ruiming Yue; Yong Zhao; Lingai Pan; Weiwei Huang; Yang Guo; Tao Yin; Lina Ma; Dingding Zhang; Xiaobo Huang
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.